UK Antifungal Drugs Market Size & Outlook, 2023-2030
UK antifungal drugs market, 2018-2030 (US$M)
Related Markets
UK antifungal drugs market highlights
- The UK antifungal drugs market generated a revenue of USD 905.7 million in 2023 and is expected to reach USD 1,215.7 million by 2030.
- The UK market is expected to grow at a CAGR of 4.3% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 905.7 million |
| Market revenue in 2030 | USD 1,215.7 million |
| Growth rate | 4.3% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.68% in 2023. Horizon Databook has segmented the UK antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
The UK Medicine and Healthcare Products Regulatory Agency (MHRA) is responsible for the regulatory affairs of pharmaceuticals in the UK. The MHRA grants permission for clinical trials, and the company seeking approval has to meet all safety standards.
The study length and approval duration depend on the drug type. The European Medicines Agency (EMA) designs procedures while ensuring strong evidence of safety, efficacy, and quality of high-potency drugs.
Recently, the EMA amended guidelines for adoption of waiver for export manufacturing Supplementary Protection Certificates (SPCs). SPCs provided extended protection for patented chemical entities to compensate for the time lost in approval.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK antifungal drugs market size, by drug class, 2018-2030 (US$M)
UK Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
